Maxim Group analyst Jason McCarthy reiterated a Purchase score on Inovio Prescribed drugs (NASDAQ:) on Friday, setting a worth goal of $20, which is roughly 89.75% above the current share worth of $10.54.
McCarthy expects Inovio Prescribed drugs to publish earnings per share (EPS) of $0.12 for the fourth quarter of 2020.
The present consensus amongst 8 TipRanks analysts is for a Maintain score of shares in Inovio Prescribed drugs, with a median worth goal of $14.17.
The analysts worth targets vary from a excessive of $25 to a low of $8.
In its newest earnings report, launched on 09/30/2020, the corporate reported a quarterly income of $236.18 thousand and a web revenue of -$36.33 million. The corporate’s market cap is $1.79 billion.
Based on TipRanks.com, Maxim Group analyst Jason McCarthy is at the moment ranked with 5 stars on a 0-5 stars rating scale, with a median return of 27.5% and a 50.12% success fee.
Inovio Prescribed drugs, Inc. is a late-stage biotechnology firm, which engages within the discovery, growth, and commercialization of DNA-based immunotherapies and vaccines. Its drug candidates embrace SynCon immunotherapies which helps break the immune system’s tolerance of cancerous cells; and CELLECTRA supply system which facilitates optimized mobile uptake of the SynCon immunotherapies. The corporate was based by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Assembly, PA.
Fusion Media or anybody concerned with Fusion Media won’t settle for any legal responsibility for loss or injury because of reliance on the knowledge together with knowledge, quotes, charts and purchase/promote indicators contained inside this web site. Please be totally knowledgeable relating to the dangers and prices related to buying and selling the monetary markets, it is among the riskiest funding varieties potential.